Sigma Planning Corp Sells 1,061 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Sigma Planning Corp lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 37.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,781 shares of the pharmaceutical company’s stock after selling 1,061 shares during the quarter. Sigma Planning Corp’s holdings in Vertex Pharmaceuticals were worth $724,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in VRTX. abrdn plc grew its position in Vertex Pharmaceuticals by 196.0% during the fourth quarter. abrdn plc now owns 581,018 shares of the pharmaceutical company’s stock worth $236,410,000 after buying an additional 384,730 shares in the last quarter. BSN CAPITAL PARTNERS Ltd acquired a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at $81,378,000. Northern Trust Corp boosted its holdings in shares of Vertex Pharmaceuticals by 4.9% in the 3rd quarter. Northern Trust Corp now owns 2,813,563 shares of the pharmaceutical company’s stock valued at $978,388,000 after purchasing an additional 131,539 shares in the last quarter. International Assets Investment Management LLC boosted its holdings in shares of Vertex Pharmaceuticals by 21,750.1% in the 4th quarter. International Assets Investment Management LLC now owns 115,150 shares of the pharmaceutical company’s stock valued at $46,853,000 after purchasing an additional 114,623 shares in the last quarter. Finally, Panagora Asset Management Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 110.1% in the 3rd quarter. Panagora Asset Management Inc. now owns 201,519 shares of the pharmaceutical company’s stock valued at $70,076,000 after purchasing an additional 105,608 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ:VRTX opened at $400.76 on Thursday. The firm has a market cap of $103.58 billion, a P/E ratio of 28.85, a P/E/G ratio of 1.91 and a beta of 0.35. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a 12-month low of $316.43 and a 12-month high of $448.40. The business has a fifty day simple moving average of $412.66 and a 200 day simple moving average of $398.38.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, topping the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The firm had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same period last year, the company posted $3.33 EPS. Analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on VRTX shares. UBS Group reduced their target price on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $440.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 20th. Wells Fargo & Company raised their target price on Vertex Pharmaceuticals from $500.00 to $540.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Canaccord Genuity Group downgraded Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and raised their target price for the company from $332.00 to $379.00 in a report on Wednesday, January 24th. Finally, Robert W. Baird cut Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price target for the company. in a research note on Wednesday, January 31st. Three research analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $429.45.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the transaction, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Amit Sachdev sold 3,222 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,381 shares of company stock valued at $5,203,249. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.